Venturi Wealth Management LLC Decreases Stock Holdings in Repligen Co. (NASDAQ:RGEN)

Venturi Wealth Management LLC decreased its stake in Repligen Co. (NASDAQ:RGEN) by 25.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,024 shares of the biotechnology company’s stock after selling 345 shares during the period. Venturi Wealth Management LLC’s holdings in Repligen were worth $147,000 as of its most recent filing with the SEC.

Other hedge funds have also added to or reduced their stakes in the company. UMB Bank n.a. raised its position in shares of Repligen by 49.1% in the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 110 shares during the period. First Turn Management LLC bought a new stake in shares of Repligen in the third quarter valued at approximately $13,202,000. Thrivent Financial for Lutherans raised its position in shares of Repligen by 6.1% in the third quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company’s stock valued at $95,037,000 after purchasing an additional 36,773 shares during the period. Geneva Capital Management LLC raised its position in shares of Repligen by 8.5% in the third quarter. Geneva Capital Management LLC now owns 138,677 shares of the biotechnology company’s stock valued at $20,638,000 after purchasing an additional 10,908 shares during the period. Finally, TimesSquare Capital Management LLC raised its position in shares of Repligen by 14.6% in the third quarter. TimesSquare Capital Management LLC now owns 275,627 shares of the biotechnology company’s stock valued at $41,019,000 after purchasing an additional 35,115 shares during the period. Institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on RGEN shares. Royal Bank of Canada upped their target price on shares of Repligen from $203.00 to $205.00 and gave the stock an “outperform” rating in a report on Friday. StockNews.com lowered shares of Repligen from a “hold” rating to a “sell” rating in a report on Friday. JPMorgan Chase & Co. upped their target price on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday. Wolfe Research started coverage on shares of Repligen in a report on Thursday, November 14th. They set a “peer perform” rating on the stock. Finally, TD Cowen started coverage on shares of Repligen in a report on Monday, February 10th. They set a “buy” rating and a $200.00 target price on the stock. One analyst has rated the stock with a sell rating, five have given a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, Repligen currently has an average rating of “Moderate Buy” and an average target price of $181.00.

Repligen Price Performance

RGEN stock opened at $158.99 on Friday. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. Repligen Co. has a one year low of $113.50 and a one year high of $203.13. The stock has a market cap of $8.91 billion, a PE ratio of -311.75, a P/E/G ratio of 4.54 and a beta of 0.99. The firm has a 50 day simple moving average of $155.22 and a two-hundred day simple moving average of $148.68.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The business had revenue of $167.55 million during the quarter, compared to analysts’ expectations of $167.58 million. On average, analysts predict that Repligen Co. will post 1.72 EPS for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.